Swedish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Clinical Drug Investigation 2000

Efficacy and Safety of Quinfamide versus Secnidazole in the Management of Amoebic Non-Dysenteric Colitis in Children.

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Länken sparas på Urklipp
N Padilla
R Díaz
M Muñoz

Nyckelord

Abstrakt

OBJECTIVE

To compare the efficacy and safety of single doses of quinfamide and secnidazole in the treatment of amoebic non-dysenteric colitis in children.

METHODS

This was a prospective, longitudinal, double-blind, randomised, comparative study.

METHODS

The participants were students or relatives of students at two urban elementary schools in Celaya, Guanajuato, Mexico.

METHODS

Patients aged between 2 and 15 years of age with cysts of Entamoeba histolytica in stool samples for 3 consecutive days as detected by Faust's concentration method were enrolled in this study.

METHODS

Single doses of quinfamide 4.3 mg/kg or secnidazole 30 mg/kg were administered. Patients were asked about the acceptability of the flavour of the drugs. Efficacy was evaluated by the presence or absence of E. histolytica cysts in stool samples on the fifth, sixth and seventh days after administration of the drugs. Adverse events were evaluated by direct questioning of patients.

RESULTS

734 patients were evaluated by coproparasitoscopy, of whom 239 (32.6%) had E. histolytica cysts. 112 patients were randomised to receive quinfamide and 127 to receive secnidazole. Differences in age, bodyweight, size and gender distribution were not statistically significant between the groups. 108 patients (96%) in the quinfamide group and 15 patients (12%) in the secnidazole group reported the flavour as good (p < 0.0001). 95 patients (85%) in the quinfamide group and 93 patients (73%) in the secnidazole group had negative stool samples at the end of treatment (p = 0.04). Nausea (p < 0.0001), abdominal pain (p < 0.05) and unpleasant taste (i.e. metallic taste 3 to 5 days after administration of secnidazole) in mouth (p < 0.0001) were more common in the secnidazole group than in the quinfamide group.

CONCLUSIONS

Quinfamide is an excellent option for amoebic non-dysenteric colitis because of its high parasitoscopic efficacy, minimum adverse effects and good acceptance by children. The single-dose schedule guarantees completion of treatment.

Gå med på vår
facebook-sida

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen

  • Fungerar på 55 språk
  • Växtbaserade botemedel som stöds av vetenskap
  • Örter igenkänning av bild
  • Interaktiv GPS-karta - märka örter på plats (kommer snart)
  • Läs vetenskapliga publikationer relaterade till din sökning
  • Sök efter medicinska örter efter deras effekter
  • Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent

Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning

Google Play badgeApp Store badge